Cumulative lead exposure and cognitive performance among elderly men

Epidemiology

Volumn 18, Issue 1, 2007, Pages 59-66

  Weisskopf, Marc G ^a   Proctor, Susan P ^b,c   Wright, Robert O ^a,d,e   Schwartz, Joel ^a   Spiro III, Avron ^b,c   Sparrow, David ^b,c,f   Nie, Huiling ^a,e   Hu, Howard ^a,e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c BOSTON UNIVERSITY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEAD;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; BONE; COGNITION; COGNITIVE DEFECT; COMMUNITY LIVING; CONTROLLED STUDY; DEPTH PERCEPTION; ELDERLY CARE; HUMAN; LEAD BLOOD LEVEL; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; MENTAL PERFORMANCE; MENTAL TASK; NEUROPSYCHOLOGICAL TEST; NONLINEAR REGRESSION ANALYSIS; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RESPONSE TIME; SCORING SYSTEM; VISUOMOTOR COORDINATION; X RAY FLUORESCENCE;

AGE FACTORS; AGED; BONE AND BONES; BOSTON; COGNITION; COGNITION DISORDERS; COHORT STUDIES; ENVIRONMENTAL EXPOSURE; HUMANS; LEAD; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 33845724066     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ede.0000248237.35363.29     Document Type: Article

References (39)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
2. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119-1122.
3. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-1992.
4. Koller K, Brown T, Spurgeon A, et al. Recent developments in low-level lead exposure and intellectual impairment in children. Environ Health Perspect. 2004;112:987-994.
5. ATSDR. Toxicological Profile for Lead. Atlanta: US Department of Health and Human Services, Public Health Service; 1999.
6. Weisskopf MG, Wright RO, Schwartz J, et al. Cumulative lead exposure and prospective change in cognition among elderly men: the VA Normative Aging Study. Am J Epidemiol. 2004;160:1184-1193.
7. Wright RO, Tsaih SW, Schwartz J, et al. Lead exposure biomarkers and Mini-Mental Status Exam scores in older men. Epidemiology. 2003;14:713-718.
8. Balbus-Kornfeld JM, Stewart W, Bolla KI, et al. Cumulative exposure to inorganic lead and neurobehavioural test performance in adults: an epidemiological review. Occup Environ Med. 1995;52:2-12.
9. Bleecker ML, Lindgren KN, Ford DP. Differential contribution of current and cumulative indices of lead dose to neuropsychological performance by age. Neurology. 1997;48:639-645.
10. Fiedler N, Weisel C, Lynch R, et al. Cognitive effects of chronic exposure to lead and solvents. Am J Ind Med. 2003;44:413-423.
11. Hanninen H, Aitio A, Kovala T, et al. Occupational exposure to lead and neuropsychological dysfunction. Occup Environ Med. 1998;55:202-209.
12. Schwartz BS, Lee BK, Bandeen-Roche K, et al. Occupational lead exposure and longitudinal decline in neurobehavioral test scores. Epidemiology. 2005;16:106-113.
13. Schwartz BS, Lee BK, Lee GS, et al. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers. Am J Epidemiol. 2001;153:453-464.
14. Schwartz BS, Stewart WF, Bolla KI, et al. Past adult lead exposure is associated with longitudinal decline in cognitive function. Neurology. 2000;55:1144-1150.
15. Stewart WF, Schwartz BS, Simon D, et al. Neurobehavioral function and tibial and chelatable lead levels in 543 former organolead workers. Neurology. 1999;52:1610-1617.
16. Payton M, Riggs KM, Spiro A 3rd, et al. Relations of bone and blood lead to cognitive function: the VA Normative Aging Study. Neurotoxicol Teratol. 1998;20:19-27.
17. Muldoon SB, Cauley JA, Kuller LH, et al. Effects of blood lead levels on cognitive function of older women. Neuroepidemiology. 1996;15:62-72.
18. Bell B, Rose CL, Damon A. The Veterans Administration longitudinal study of healthy aging. Gerontologist. 1966;6:179-184.
19. Hu H, Aro A, Payton M, et al. The relationship of bone and blood lead to hypertension. The Normative Aging Study. JAMA. 1996;275:1171-1176.
20. Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect. 1998;106:1-8.
21. Letz R. NES2 User's Manual (version 4. 4). Winchester, MA: Neurobehavioral Systems, Inc; 1991.
22. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: Harcourt, Brace Janovich; 1981.
23. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39:1159-1165.
24. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40:922-935.
25. Beery KE, Buktenica NA. Developmental Test of Visual-Motor Integration. Odessa, FL: Psychological Assessment Resources; 1989.
26. Kim R, Landrigan C, Mossmann P, et al. Age and secular trends in bone lead levels in middle-aged and elderly men: three-year longitudinal follow-up in the Normative Aging Study. Am J Epidemiol. 1997;146:586-591.
27. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2004.
28. Rosner B. Percentage points for a generalized ESD many-outliers procedure. Technometrics. 1983;25:165-172.
29. Stollery BT. Reaction time changes in workers exposed to lead. Neurotoxicol Teratol. 1996;18:477-483.
30. Stollery BT, Broadbent DE, Banks HA, et al. Short term prospective study of cognitive functioning in lead workers. Br J Ind Med. 1991;48:739-749.
31. White RF, Feldman RG, Travers PH. Neurobehavioral effects of toxicity due to metals, solvents, and insecticides. Clin Neuropharmacol. 1990;13:392-412.
32. Braga MF, Pereira EF, Albuquerque EX. Nanomolar concentrations of lead inhibit glutamatergic and GABAergic transmission in hippocampal neurons. Brain Res. 1999;826:22-34.
33. Goldstein GW. Evidence that lead acts as a calcium substitute in second messenger metabolism. Neurotoxicology. 1993;14:97-101.
34. Lasley SM, Gilbert ME. Glutamatergic components underlying leadinduced impairments in hippocampal synaptic plasticity. Neurotoxicology. 2000;21:1057-1068.
35. Minnema DJ, Greenland RD, Michaelson IA. Effect of in vitro inorganic lead on dopamine release from superfused rat striatal synaptosomes. Toxicol Appl Pharmacol. 1986;84:400-411.
36. Salthouse TA. The processing-speed theory of adult age differences in cognition. Psychol Rev. 1996;103:403-428.
37. Acharya S, Acharya UR. In vivo lipid peroxidation responses of tissues in lead-treated Swiss mice. Ind Health. 1997;35:542-544.
38. Ercal N, Treeratphan P, Hammond TC, et al. In vivo indices of oxidative stress in lead-exposed C57BL/6 mice are reduced by treatment with meso-2,3-dimercaptosuccinic acid or N- acetylcysteine. Free Radic Biol Med. 1996;21:157-161.
39. Widzowski DV, Cory-Slechta DA. Homogeneity of regional brain lead concentrations. Neurotoxicology. 1994;15:295-307.